FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ DCP-RPMIGH-QPBR1X is an MPS-grade, ultra-filtered RPMI 1640 cell-culture medium engineered for organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. This high-glucose, 25 mM HEPES-buffered, bicarbonate-free and phenol-red-free formulation is processed through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), finishing with a 0.04 µm final polish for microchannel-safe purity.

• RPMI 1640 base with high glucose (4500 mg/L D-Glucose) and 25 mM HEPES buffering
• Bicarbonate-free and phenol-red-free formulation; L-Glutamine and Sodium Pyruvate not added
• HEPES-buffered for reduced CO₂ dependence — validate per cell line
• Endotoxin specification: NMT 5 EU/mL (BET, USP <85>)
• Quadruple-stage filtration (0.1 µm ×2 + 0.04 µm ×2) with a 0.04 µm final polish
• 37 defined components verified per lot with full CAS traceability
• Manufactured under ISO 13485-certified, CE-approved facilities; final QC at Diagnocine, Totowa NJ
• Customization available: pH, glucose, HEPES, salts, and nutrients on request

Engineered where standard media fails

Conventional 0.22 µm–filtered media can pass mycoplasma, subvisible particulates, and aggregates that foul microfluidic channels and confound on-chip assays. FluxMPS™ addresses these failure modes through a 0.04 µm final-polish architecture and a fully defined, traceable formulation.

Quadruple-stage filtration system

Four serial filtration stages culminate in a 0.04 µm final polish under aseptic fill & finish — delivering a ready-to-use medium at a purity level beyond conventional 0.22 µm filtration.

1. 1

   0.1 µm Pre-filtration I — Large Particulate Removal

   Removes large aggregates and debris; protects downstream 0.04 µm membranes and extends their service life.

2. 2

   0.04 µm Pre-filtration II — Mycoplasma Barrier

   Retains mycoplasma (0.1–0.3 µm) — not achievable with standard 0.22 µm filtration. First sub-mycoplasma polishing stage.

3. 3

   0.1 µm Sterile-filtration I — Second-pass Redundancy

   Second-pass sterility redundancy; ensures no breakthrough from Stage 1. Independent sterility assurance.

4. 4

   0.04 µm Sterile-filtration II — Final Polish

   Ultimate sub-mycoplasma polish followed by aseptic fill & finish. Final product QC release gate.

OoC and MPS applications

FluxMPS™ DCP-RPMIGH-QPBR1X delivers ultra-filtered, HEPES-buffered RPMI 1640 for organ-on-a-chip, microfluidic, and metabolic research where particulate-free media and defined nutrient control are critical.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra-filtered variant is available on request for automated bioreactors and robotic perfusion systems that demand the lowest possible particulate load.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates that foul automated systems
• Valve & Sensor Protection: Reduces micro-fouling in automated perfusion and recirculation systems
• Extended Perfusion Stability: Consistent nutrient delivery over long-duration culture runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm ultra-filtered variant.

Analytical release specifications

Every lot is released against the product specification. A Certificate of Analysis is available: support@diagnocine.com.

Full composition (mg/L)

RPMI 1640 Medium, High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid — 37 ingredients verified per lot with CAS numbers for full raw-material traceability. All ingredients from the original formulation are preserved exactly.

ISO 13485 manufacturing & compliance

Every batch of FluxMPS™ DCP-RPMIGH-QPBR1X is manufactured under a certified ISO 13485:2016 QMS in CE-approved facilities, with full lot traceability and multi-parameter QC release testing; final QC is performed at Diagnocine, Totowa NJ.

How DCP-RPMIGH-QPBR1X compares

FluxMPS™ versus conventional 0.22 µm filtered RPMI 1640 media for OoC and MPS applications.

Frequently asked questions

Common questions about FluxMPS™ DCP-RPMIGH-QPBR1X and its use in OoC and MPS applications.

Supporting literature

Curated peer-reviewed references relevant to OoC and MPS applications and to HEPES-buffered RPMI 1640 cell-culture media.

1. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature Biotechnology. 2014;32(8):760–772.doi:10.1038/nbt.2989
2. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–189.doi:10.1038/nature13118
3. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
4. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics. 2022;23:467–491.doi:10.1038/s41576-022-00466-9
5. Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit. Nature Biotechnology. 2018;36:865–874.doi:10.1038/nbt.4226
6. Bhise NS, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.doi:10.1088/1758-5090/8/1/014101
7. Moore GE, Gerner RE, Franklin HA. Culture of normal human leukocytes. JAMA. 1967;199(8):519–524.doi:10.1001/jama.1967.03120080053007
8. Good NE, et al. Hydrogen ion buffers for biological research. Biochemistry. 1966;5(2):467–477.doi:10.1021/bi00866a011
9. van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Current Opinion in Biotechnology. 2015;35:118–126.doi:10.1016/j.copbio.2015.05.002
10. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.doi:10.1126/science.123.3191.309